Warrington Jessica Isabel, Richards Gareth Owain, Wang Ning
The Mellanby Centre for Bone Research, Department of Oncology and Metabolism, The University of Sheffield, Beech Hill Road, Sheffield, S10 2RX UK.
Curr Mol Biol Rep. 2017;3(3):197-203. doi: 10.1007/s40610-017-0071-9. Epub 2017 Aug 2.
This study is to highlight recent discoveries associated with the role of calcitonin peptide family and their receptors in prostate cancer progression and bone metastasis.
Studies have linked adrenomedullin (AM), calcitonin (CT) and calcitonin gene-related peptide (CGRP) to the spread of prostate tumours to the bone. AM can induce a metastatic phenotype in prostate cancer cells through its action on TRPV2 calcium channels and is also capable of influencing localised levels of RANKL in the bone to favour tumourigenesis. CT utilises A-kinase anchoring proteins to indirectly act on PKA and promote metastasis in prostate cancer. The receptor for CT contains a PDZ-binding domain, the deletion of which stops metastasis to the bone in orthotopic prostate models.
Recent findings show strong evidence for the role of calcitonin peptides and receptors in prostate cancer and bone metastasis. Further research could provide potential prognostic markers and therapeutic targets for prostate cancer patients.
本研究旨在强调降钙素肽家族及其受体在前列腺癌进展和骨转移中作用的最新发现。
研究已将肾上腺髓质素（AM）、降钙素（CT）和降钙素基因相关肽（CGRP）与前列腺肿瘤向骨的扩散联系起来。AM可通过作用于TRPV2钙通道在前列腺癌细胞中诱导转移表型，并且还能够影响骨中RANKL的局部水平以促进肿瘤发生。CT利用A激酶锚定蛋白间接作用于蛋白激酶A（PKA）并促进前列腺癌转移。CT受体含有一个PDZ结合结构域，在原位前列腺模型中删除该结构域可阻止向骨转移。
最新研究结果有力证明了降钙素肽及其受体在前列腺癌和骨转移中的作用。进一步的研究可为前列腺癌患者提供潜在的预后标志物和治疗靶点。
